SCHEMBL2705545

SCHEMBL2705545

CNC(=O)c1cc(Oc2ccc(N(C(N)=O)c3cc(C(F)(F)F)ccc3OC)cc2)ccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 13/20 0.62
KDR P35968 5/20 0.53
PLK4 O00444 2/20 0.53
AURKA O14965 2/20 0.53
MAPK13 O15264 2/20 0.53
MAP4K4 O95819 2/20 0.53
ABL1 P00519 2/20 0.53
LCK P06239 2/20 0.53
FYN P06241 2/20 0.53
LYN P07948 2/20 0.53
RET P07949 2/20 0.53
SRC P12931 2/20 0.53
RPS6KB1 P23443 2/20 0.53
EPHA2 P29317 2/20 0.53
AXL P30530 2/20 0.53
FRK P42685 2/20 0.53
MAPK9 P45984 2/20 0.53
BLK P51451 2/20 0.53
CAMK2B Q13554 2/20 0.53
NTRK3 Q16288 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2702766 0.91 RAF1 (0.56) RAF1KDRPLK4AURKAMAPK13
SCHEMBL2704342 0.91 RAF1 (0.51) RAF1KDRPLK4AURKAMAPK13
SCHEMBL7964989 0.90 RAF1 (0.53) RAF1KDRPLK4AURKAMAPK13
SCHEMBL2704986 0.86 RAF1 (0.46) RAF1KDRPLK4AURKAMAPK13
SCHEMBL6012171 0.85 RAF1 (0.56) RAF1KDRPLK4AURKAMAPK13
SCHEMBL6249040 0.85 RAF1 (0.43) RAF1KDRMAPK14TNNI3KBRAF
SCHEMBL13388575 0.84 RAF1 (0.61) RAF1KDRMAPK1
SCHEMBL2704896 0.82 RAF1 (0.46) RAF1KDRPLK4AURKAMAPK13
SCHEMBL177543 0.82 KDR (0.60) RAF1KDRPLK4AURKAMAPK13
SCHEMBL5089023 0.79 BRAF (0.46) RAF1KDRPLK4AURKAMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298311-B1 w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors BAYER HEALTHCARE LLC (US) 2012-05-09 EP claimed
US-20010034447-A1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC 2001-10-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034447-A1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BRAF, RAF1, ARAF RAF1 2/4885KDR 567/4885PLK4 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.